Clinical experience with paliperidone palmitate in a specialty hospital in the Philippines: A short report

ABSTRACT Objective To describe the clinical outcomes related to the introduction of paliperidone palmitate in a specialty hospital in the Philippines Design Cross-sectional study among patients seen at the psychiatry service of a specialty hospital catering to veterans who were initiated on paliperidone palmitate. We reviewed and abstracted baseline patient data from the medical record of eligible patients. Outcome of treatment was collected through a one-time objective assessment of the patient by a third-party psychiatrist using the Structured Clinical Interview for Symptoms of Remission (SCI-SR) tool. Main Result A total of 30 patients were recruited for the study from August 2020 and June 2021, the majority of whom were males (80%), residents of the National Capital Region (50%), and single (20%). The median duration from schizophrenia diagnosis to initiation of paliperidone treatment was 19.50 years (IQR: 16.60 – 33.50). In eight patients (22.67%), other antipsychotic drugs were discontinued following initiation of paliperidone treatment; in the remaining 22 participants (73.33%), paliperidone was taken concurrently with other antipsychotic drugs. The median duration from the initiation of paliperidone treatment to follow-up assessment was 27.20 months (IQR: 24.73 – 30.50), with all participants having at least 6 months of treatment. At follow-up assessment, all participants were classified to be in remission. Conclusion In this study among patients with schizophrenia seen in a specialty hospital in the Philippines, we found evidence that clinical outcomes with paliperidone palmitate were comparable to those given a combination of oral and long-acting antipsychotics.